trial

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

NCTId NCT04105231
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 64 (estimated)
Sponsored by Lone Baandrup
Primary completion 2025-11-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
64 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-06-01
Primary completion
2025-11-25
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
CannabidiolRisperidone

Sponsors

Lone BaandrupLead Sponsor
Danish Center for Sleep MedicineCollaborator
Copenhagen University Hospital, DenmarkCollaborator
Glostrup University Hospital, CopenhagenCollaborator
University of CopenhagenCollaborator

Investigators

1
Lone Baandrup, MD, PhDPrincipal Investigator

Sites

1 total
Glostrup Municipality, Denmark

Linked catalysts

1
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use — primary completion2025-11-25

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE2
Primary Completion Date
2025-11-25
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Cannabidiol
drug
Risperidone
drug
lead_sponsor
Lone Baandrup
company
collaborator
Danish Center for Sleep Medicine
company
Copenhagen University Hospital, Denmark
company
indication
Marijuana Abuse
indication
Dual Diagnosis
indication
Psychotic Disorders
indication
investigator
Lone Baandrup, MD, PhD
person